logo

Ce site web utilise des cookies

Ces cookies recueillent un certain nombre d’informations, de façon anonyme, lors de vos visites sur notre site. Ils permettent de mesurer l'activité du site web et d'établir des statistiques analytiques de la fréquentation et de l'utilisation des différents contenus et rubriques de notre site internet. En poursuivant votre navigation sur ce site, vous acceptez l'utilisation de ces cookies. Pour plus d'informations, veuillez consulter les Conditions Générales d’Utilisation

  • Centre de détection précoce Marrakech
  • Marrakech  -  

    HRH Princess Lalla Salma, president of the Lalla Salma Foundation for Cancer Prevention and Treatment inaugurated, on Monday 19 May in Marrakech, a reproductive health reference center for breast and uterine cancer early detection.

    The setting up of the center is part of the national program for breast and uterine cancer early detection which is developed in collaboration with the Health Ministry.

    The center offers 4,500 consultations per year for breast and uterine cancer screening and early diagnosis. The center's construction and equipment, over a surface area of 700 square meters, is worth 6.1 mln dirhams funded by the Al Waleed Bin Talal Foundation, social security body CNOPS and the Lalla Salma Foundation for Cancer Prevention and Treatment.

    The center is part of the broadening of the program on uterine cancer early detection in the prefecture of Marrakech. The nation-wide program on breast cancer screening and early diagnosis targets a population of 3.4 million women.

    The activities of the program on uterine cancer early detection are ensured in six regions: Rabat Salé Zemmour Zaïr, Meknès Tafilalt, Fez Boulmane, Marrakech Tensift El Haouz, Greater Casablanca, and Gharb Chrarda Bni Hssein. It covers a targeted population of 1.5 million women.

    As for the prefecture of Marrakech, the program for breast and uterine cancer early detection targets a population of 166,000 women aged 45-69 for breast cancer screening and nearly 122,000 women aged 30-49 for uterine cancer.